9-Feb-2026
Invesco QQQ Trust ETF (QQQ) Daily Update, 2/9/2026
TipRanks (Mon, 9-Feb 7:35 AM ET)
Notable healthcare headlines for the week: Pfizer Novo Nordisk in focus
Seeking Alpha News (Sun, 8-Feb 9:05 AM ET)
Amgen (AMGN) Receives a Buy from Argus Research
TipRanks (Fri, 6-Feb 11:25 PM ET)
Dow smashes 50,000 and here’s how all 30 stocks rank according to SA Quant Ratings
Seeking Alpha News (Fri, 6-Feb 3:49 PM ET)
Dow tops 50,000 for the first time as the blue-chip rally accelerates
Seeking Alpha News (Fri, 6-Feb 3:21 PM ET)
Amgen Advances Xaluritamig Into Early-Stage Trial for Hard-to-Treat Ewing Sarcoma
TipRanks (Fri, 6-Feb 11:33 AM ET)
Guggenheim Remains a Hold on Amgen (AMGN)
TipRanks (Fri, 6-Feb 7:46 AM ET)
President Trump unveils TrumpRx website for low-cost prescription drugs
Seeking Alpha News (Fri, 6-Feb 1:48 AM ET)
CVS Health to swap Amgen and Lilly’s bone drugs with biosimilars in commercial formularies
Seeking Alpha News (Thu, 5-Feb 12:46 PM ET)
Seeking Alpha News (Thu, 5-Feb 12:20 PM ET)
Amgen is a leader in biotechnology-based human therapeutics. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drugs Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx Pharmaceuticals bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). The 2023 Horizon acquisition brought several rare-disease drugs, including thyroid eye disease drug Tepezza. Amgen also has a growing biosimilar portfolio.
Amgen trades on the NASDAQ stock market under the symbol AMGN.
As of February 9, 2026, AMGN stock price declined to $375.82 with 2,669,097 million shares trading.
AMGN has a beta of 0.23, meaning it tends to be less sensitive to market movements. AMGN has a correlation of 0.02 to the broad based SPY ETF.
AMGN has a market cap of $202.33 billion. This is considered a Mega Cap stock.
Last quarter Amgen reported $10 billion in Revenue and $5.29 earnings per share. This beat revenue expectation by $402 million and exceeded earnings estimates by $.54.
In the last 3 years, AMGN traded as high as $385.12 and as low as $211.71.
The top ETF exchange traded funds that AMGN belongs to (by Net Assets): VTI, QQQ, VOO, SCHD, IVV.
AMGN has outperformed the market in the last year with a price return of +29.4% while the SPY ETF gained +15.7%. AMGN has also outperformed the stock market ETF in the last 3 month and 2 week periods returning +19.8% and +9.0%, respectively, while the SPY returned +3.8% and +0.7%, respectively.
AMGN support price is $376.40 and resistance is $392.24 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that AMGN shares will trade within this expected range on the day.